419 active not recruiting. 419 Phase 2, 101 Phase 1, 23 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 419 | Active not recruiting 419 |
| Phase 1 | 101 | Active not recruiting 101 |
| Phase 3 | 23 | Active not recruiting 23 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 140 | 2026-07-01 | 2026-07-17 |
| Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI eparlitozoviril, Control group - HCC - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-06-12 | 2026-06-18 |
| Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Harbin Medical University | 96 | 2026-06-10 | 2026-07-02 |
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer Anlotinib + Cadonilimab, PULSAR - Previously Treated, Advanced, Biliary Tract Cancers | Phase 2 | Active not recruiting | West China Hospital | 26 | 2026-06-03 | 2026-06-09 |
| Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. Sintilimab + Ipilimumab (N01) + AG, Sintilimab Combined with Albumin-bound Paclitaxel and Gemcitabine (AG) - Biliary Tract Cancers (BTC) | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 107 | 2026-04-24 | 2026-06-17 |
| Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE) Conversion Surgery, Systemic Therapy/Standard of Care - Gastric Cancer Stage IV, Peritoneal Metastasis | Phase 2 / Phase 3 | Active not recruiting | National University Hospital, Singapore | 300 | 2026-02-21 | 2026-05-14 |
| Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial TACE-HAIC+T-B, HAIC+T-B, TACE+T-B - Hepatocellular Carcinoma (HCC) | Phase 2 | Active not recruiting | Sun Yat-sen University | 90 | 2026-01-23 | 2026-02-02 |
| Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma lpromlimab and Tuvonralimab lpromlimab and Tuvonralimab Combined with Albumin-Bound Paclitaxel and Nedaplatin - Locally Advanced, Resectable | Phase 2 | Active not recruiting | Sun Yat-sen University | 62 | 2025-12-17 | 2026-01-28 |
| Maxigesic for Postoperative Pain Control After Laparoscopic or Robotic Gastrectomy Acetaminophen and Ibuprofen, Acetaminophen - Stomach Neoplasms | Phase 2 | Active not recruiting | Seoul National University Bundang Hospital | 90 | 2025-11-21 | 2026-08-17 |
| A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) Navlimetostat, Gemcitabine, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 470 | 2025-10-23 | 2026-06-03 |
| Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen Arm A:Dose_dense Capecitabine in Colorectal cancer, Arm B : standard dose Capecitabine - Colorectal Cancer | Phase 2 | Active not recruiting | Sohag University | 100 | 2025-09-25 | 2025-10-14 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 AZD0901 - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Active not recruiting | AstraZeneca | 33 | 2025-08-29 | 2026-09-30 |
| The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT) Ipalolimab and Tovorilimab - dMMR/MSI-H-type Rectal Adenocarcinoma | Phase 2 | Active not recruiting | Sir Run Run Shaw Hospital | 29 | 2025-08-20 | 2025-12-02 |
| A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer narmafotinib ascending doses, narmafotinib dose comparison - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Amplia Therapeutics Limited | 67 | 2025-08-18 | 2026-05-05 |
| A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma Combination therapy (COMB) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | First Affiliated Hospital of Zhejiang University | 35 | 2025-08-06 | 2025-08-26 |
| Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Durvalumab, Tremelimumab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | AstraZeneca | 114 | 2025-08-05 | 2026-10-13 |
| A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706 - Hepatocellular Carcinoma (HCC), Second Line Treatment | Phase 2 | Active not recruiting | Sun Yat-sen University | 62 | 2025-08-01 | 2026-04-29 |
| A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer SHR-8068 Injection, Adebrelimab Injection, Bevacizumab Injection - Colorectal Cancer | Phase 2 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 103 | 2025-07-22 | 2026-08-11 |
Showing 20 of 419. Sign in to see all of them.
Colorectal Neoplasms (120) · Pancreatic Neoplasms (84) · Stomach Neoplasms (67) · Carcinoma, Hepatocellular (55) · Rectal Neoplasms (40) · Carcinoma, Non-Small-Cell Lung (39) · Esophageal Neoplasms (31) · Colonic Neoplasms (29) · Neoplasms (24) · Biliary Tract Neoplasms (23) · Melanoma (19) · Neoplasm Metastasis (19) · Breast Neoplasms (18) · Esophageal Squamous Cell Carcinoma (18) · Cholangiocarcinoma (17)
Digestive System Diseases (417) · Neoplasms by Site (408) · Neoplasms (395) · Gastrointestinal Diseases (274) · Gastrointestinal Neoplasms (267) · Intestinal Diseases (174) · Intestinal Neoplasms (174) · Rectal Diseases (158) · Colonic Diseases (135) · Neoplasms by Histologic Type (135) · Neoplasms, Glandular and Epithelial (123) · Carcinoma (117) · Endocrine Gland Neoplasms (106) · Endocrine System Diseases (106)
Oxaliplatin (47) · Capecitabine (42) · Fluorouracil (42) · pembrolizumab (40) · Bevacizumab (37) · Gemcitabine (35) · Leucovorin (34) · Nivolumab (30) · durvalumab (27) · Cisplatin (25) · Magnetic Resonance Spectroscopy (25) · Specimen Handling (25) · atezolizumab (21) · Biopsy (20) · Irinotecan (20)
National Cancer Institute (NCI) (28) · M.D. Anderson Cancer Center (19) · AstraZeneca (12) · Memorial Sloan Kettering Cancer Center (12) · Sun Yat-sen University (12) · Fudan University (7) · Alliance for Clinical Trials in Oncology (5) · City of Hope Medical Center (5) · The Netherlands Cancer Institute (5) · Asan Medical Center (4) · Astellas Pharma Global Development, Inc. (4) · ECOG-ACRIN Cancer Research Group (4) · Eli Lilly and Company (4) · GlaxoSmithKline (4) · Massachusetts General Hospital (4)
United States (237) · China (98) · Spain (57) · France (53) · South Korea (48) · Canada (45) · Italy (38) · United Kingdom (37) · Australia (35) · Japan (34) · Germany (32) · Taiwan (32) · Netherlands (26) · Belgium (25) · Denmark (20)
Myriam Chalabi, MD (3) · Van K Morris (3) · Alisha Bent, MD (2) · Baruch Brenner, Prof (2) · Benjamin Weinberg, MD (2) · Changhoon Yoo, MD, PhD (2) · Dae Won Kim, MD (2) · Julie Koenig, MD (2)
PMID 35623069, PMID 26187751, PMID 31401903, PMID 37934000, PMID 40340830, PMID 40341124, PMID 10581077, PMID 11556297, PMID 15928658, PMID 21365500, PMID 21444866, PMID 21458303, PMID 21494121, PMID 21584903, PMID 21816436, PMID 21865946, PMID 22127070, PMID 22189752, PMID 22225488, PMID 22285199, PMID 22595848, PMID 23096768, PMID 23303141, PMID 23456389, PMID 23664139, PMID 24327518, PMID 24514954, PMID 24618998, PMID 24646562, PMID 24662266, PMID 24889903, PMID 25943068, PMID 26010778, PMID 26028255, PMID 26412280, PMID 26497495, PMID 26586415, PMID 26808342, PMID 26865277, PMID 27156933, PMID 27424289, PMID 28053024, PMID 28102259, PMID 28223062, PMID 28241187, PMID 28457713, PMID 28622514, PMID 28672195, PMID 28841916, PMID 28911061
2023 (13), U10CA180820 (9), 2015 (8), 2019 (6), P30CA033572 (6), U10CA180821 (5), 2017 (4), 2025 (4), P30CA015083 (4), P30CA060553 (4), 2018 (3), U10CA180888 (3), UG1CA242643 (3), 2016 (2), N01CM00032 (2)